Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma
05:18am, Saturday, 31'st May 2025
FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 mill
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript
12:02pm, Thursday, 08'th May 2025
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Dal
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
12:00pm, Thursday, 08'th May 2025
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics
08:05pm, Wednesday, 07'th May 2025
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
07:31pm, Wednesday, 07'th May 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
04:14pm, Wednesday, 07'th May 2025
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sus
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 30'th Apr 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
08:03am, Wednesday, 30'th Apr 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-lice
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
08:03am, Tuesday, 22'nd Apr 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
04:50pm, Thursday, 03'rd Apr 2025
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst tradin
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 28'th Mar 2025
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win
12:21pm, Thursday, 27'th Mar 2025
This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.
Strong Revenue, Drug Performance Lift Catalyst Shares
08:12am, Wednesday, 26'th Mar 2025
Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
12:10pm, Tuesday, 25'th Mar 2025
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in t
